Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Accumulated Expenses (2021 - 2022)

Acro Biomedical (ACBM) has 2 years of Accumulated Expenses data on record, last reported at $19.8 million in Q1 2022.

  • For Q1 2022, Accumulated Expenses changed N/A year-over-year to $19.8 million; the TTM value through Mar 2022 reached $19.8 million, changed N/A, while the annual FY2021 figure was $23.8 million, N/A changed from the prior year.
  • Accumulated Expenses reached $19.8 million in Q1 2022 per ACBM's latest filing, down from $23.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $23.8 million in Q4 2021 and bottomed at $18.5 million in Q2 2021.